igc pharma - IGC
IGC
Close Chg Chg %
0.29 -0.00 -0.58%
Open Market
0.29
0.00 (0.58%)
Volume: 182.45K
Last Updated:
Sep 9, 2026, 11:24 AM EDT
Company Overview: igc pharma - IGC
IGC Key Data
| Open $0.29 | Day Range 0.29 - 0.30 |
| 52 Week Range 0.24 - 0.45 | Market Cap $31.02M |
| Shares Outstanding 103.38M | Public Float 75.39M |
| Beta 0.49 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.08 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.11M |
IGC Performance
| 1 Week | -2.72% | ||
| 1 Month | 12.98% | ||
| 3 Months | 3.54% | ||
| 1 Year | -28.58% | ||
| 5 Years | -81.05% |
IGC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
About igc pharma - IGC
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
IGC At a Glance
IGC Pharma, Inc.
10224 Falls Road
Potomac, Maryland 20854
| Phone | 1-301-983-0998 | Revenue | 1.16M | |
| Industry | Biotechnology | Net Income | -5,527,986.18 | |
| Sector | Health Technology | Employees | 70 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
IGC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 21.579 |
| Price to Book Ratio | 3.603 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.447 |
| Enterprise Value to Sales | 20.895 |
| Total Debt to Enterprise Value | 0.006 |
IGC Efficiency
| Revenue/Employee | 16,552.34 |
| Income Per Employee | -78,971.231 |
| Receivables Turnover | 96.555 |
| Total Asset Turnover | N/A |
IGC Liquidity
| Current Ratio | 0.83 |
| Quick Ratio | 0.527 |
| Cash Ratio | 0.435 |
IGC Profitability
| Gross Margin | 1.726 |
| Operating Margin | -891.254 |
| Pretax Margin | -477.10 |
| Net Margin | -477.10 |
| Return on Assets | N/A |
| Return on Equity | N/A |
| Return on Total Capital | -73.044 |
| Return on Invested Capital | N/A |
IGC Capital Structure
| Total Debt to Total Equity | 1.953 |
| Total Debt to Total Capital | 1.916 |
| Total Debt to Total Assets | 1.493 |
| Long-Term Debt to Equity | 1.792 |
| Long-Term Debt to Total Capital | 1.757 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Igc Pharma - IGC
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 397.00K | 911.00K | 1.34M | 1.16M | |
Sales Growth
| -55.79% | +129.47% | +47.64% | -13.85% | |
Cost of Goods Sold (COGS) incl D&A
| 830.00K | 1.07M | 1.18M | 1.14M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 651.00K | 657.00K | 637.00K | 432.00K | |
Depreciation
| 627.00K | 600.00K | 563.00K | 376.00K | |
Amortization of Intangibles
| 24.00K | 57.00K | 74.00K | 56.00K | |
COGS Growth
| -33.44% | +28.80% | +9.92% | -3.09% | |
Gross Income
| (433.00K) | (158.00K) | 170.00K | 20.00K | |
Gross Income Growth
| -24.07% | +63.51% | +207.59% | -88.24% | |
Gross Profit Margin
| -109.07% | -17.34% | +12.64% | +1.73% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 14.99M | 11.41M | 9.97M | 10.35M | |
Research & Development
| 2.33M | 3.46M | 3.77M | 5.23M | |
Other SG&A
| 12.66M | 7.95M | 6.20M | 5.12M | |
SGA Growth
| +79.04% | -23.89% | -12.66% | +3.80% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | (381.00K) | 3.35M | - |
EBIT after Unusual Expense
| (15.05M) | (11.57M) | (13.14M) | (10.33M) | |
Non Operating Income/Expense
| 31.00K | 65.00K | 143.00K | 4.80M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (15.02M) | (11.51M) | (13.00M) | (5.53M) | |
Pretax Income Growth
| -70.42% | +23.38% | -12.98% | +57.48% | |
Pretax Margin
| -3,782.37% | -1,263.01% | -966.54% | -477.10% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (15.02M) | (11.51M) | (13.00M) | (5.53M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (15.02M) | (11.51M) | (13.00M) | (5.53M) | |
Net Income Growth
| -70.42% | +23.38% | -12.98% | +57.48% | |
Net Margin Growth
| -3,782.37% | -1,263.01% | -966.54% | -477.10% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (15.02M) | (11.51M) | (13.00M) | (5.53M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (15.02M) | (11.51M) | (13.00M) | (5.53M) | |
EPS (Basic)
| -0.3004 | -0.2188 | -0.2209 | -0.0471 | |
EPS (Basic) Growth
| -43.05% | +27.16% | -0.96% | +78.68% | |
Basic Shares Outstanding
| 49.99M | 52.58M | 58.84M | 88.85M | |
EPS (Diluted)
| -0.3004 | -0.2188 | -0.2209 | -0.0471 | |
EPS (Diluted) Growth
| -43.05% | +27.16% | -0.96% | +78.68% | |
Diluted Shares Outstanding
| 49.99M | 52.58M | 58.84M | 88.85M | |
EBITDA
| (14.78M) | (10.91M) | (9.16M) | (9.89M) | |
EBITDA Growth
| -79.20% | +26.14% | +16.06% | -8.01% | |
EBITDA Margin
| -3,722.17% | -1,198.02% | -681.12% | -853.97% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 5.50 | |
| Number of Ratings | 1 | Current Quarters Estimate | -0.02 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -0.10 | |
| Last Quarter’s Earnings | -0.03 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.05 | Next Fiscal Year Estimate | -0.08 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 1 | 1 | 1 | 1 |
| Mean Estimate | -0.02 | -0.02 | -0.10 | -0.08 |
| High Estimates | -0.02 | -0.02 | -0.10 | -0.08 |
| Low Estimate | -0.02 | -0.02 | -0.10 | -0.08 |
| Coefficient of Variance | N/A | N/A | N/A | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Igc Pharma - IGC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Igc Pharma - IGC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 7, 2026 | Richard K. Prins Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Claudia Grimaldi PFO; Director | 221,538 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Claudia Grimaldi PFO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Claudia Grimaldi PFO; Director | 1,372,714 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $0.26 per share | 356,905.64 |
| Apr 7, 2026 | Claudia Grimaldi PFO; Director | 1,234,252 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | James Patrick Moran Director | 50,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | James Patrick Moran Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | James Patrick Moran Director | 1,235,735 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | James Patrick Moran Director | 1,185,735 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Richard K. Prins Director | 70,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Ram Mukunda CEO; Director | 4,326,011 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Richard K. Prins Director | 1,541,251 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Richard K. Prins Director | 1,471,251 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Ram Mukunda CEO; Director | 33,334 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Ram Mukunda CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Ram Mukunda CEO; Director | 676,925 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Ram Mukunda CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Ram Mukunda CEO; Director | 910,751 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Ram Mukunda CEO; Director | 877,419 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2026 | Ram Mukunda CEO; Director | 4,649,088 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $0.26 per share | 1,208,762.88 |